ALSERES PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 USD | -50.00% |
|
-.--% | -.--% |
| Sales 2012 | 0.53 44.28 | Sales 2013 | 0.47 39.52 | Capitalization | 720K 60.06M |
|---|---|---|---|---|---|
| Net income 2012 | -1M -83.43M | Net income 2013 | - 0 | EV / Sales 2012 | 1,56,97,473 x |
| Net Debt 2012 | 5.88M 491M | Net Debt 2013 | 8.01M 668M | EV / Sales 2013 | 1,84,26,686 x |
| P/E ratio 2012 * |
-
| P/E ratio 2013 |
-
| Employees | 3 |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 33.8% |
More Fundamentals
* Assessed data
More news
| 1 day | -50.00% |
1 year
0.01
0.01
3 years
0.018.00
5 years
0.0115.50
10 years
0.011 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Savas
CEO | Chief Executive Officer | 75 | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Savas
CEO | Chief Executive Officer | 75 | 01/04/01 |
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). The Company's lead product candidate is Altropane. The Company's Altropane product is a molecular imaging agent used to diagnose Parkinson's disease and dementia. The Company is focused on entering into partnerships to ensure development and commercialization of its product.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 30 | |
| -22.83% | 1.45B | |
| -19.01% | 56.28M |
- Stock Market
- Equities
- ALSE Stock
